The beginning of the new era of monoclonal antibodies biosimilars use in oncology:current international guidelines and the results of clinical trial of the first Russian rituximab biosimilar in patients with B-cell non-Hodgkin’s lymphoma

The beginning of the new era of monoclonal antibodies biosimilars use in oncology:current international guidelines and the results of clinical trial of the first Russian rituximab biosimilar in patients with B-cell non-Hodgkin’s lymphoma

This article contains the detailed analysis of current approach to non-clinical and clinical development of monoclonal antibody biosimilars which is described in current guidelines of the European Medicines Agency (2012). Requirements of European regulatory authorities regarding evidence, which allo...

Full description

Bibliographic Details
Main Authors: K D Kaplanov, A Yu Zaritskey, S M Alekseev, R A Ivanov, E V Chernyaeva
Format: Article
Language:Russian
Published: IP Habib O.N. 2014-06-01
Series:Современная онкология
Subjects:
cd20
biosimilars
monoclonal antibodies
rituximab
b-cell non-hodgkin’s lymphoma
Online Access:https://modernonco.orscience.ru/1815-1434/article/view/26947

Similar Items

Similar Items